The Multiple Faces of Prostaglandin E2 G-Protein Coupled Receptor Signaling during the Dendritic Cell Life Cycle

Sandra De Keijzer 1, Marjolein B. M. Meddens 1, Ruurd Torensma 1 and Alessandra Cambi 1,2,*

1 Department of Tumor Immunology, Nijmegen Centre for Molecular Life Sciences, Radboud University Nijmegen Medical Centre, Geert Grooteplein 28, Nijmegen 6525GA, The Netherlands; E-Mails: s.dekeijzer@ncmls.ru.nl (S.D.K.); m.meddens@ncmls.ru.nl (M.B.M.M.); r.torensma@ncmls.ru.nl (R.T.)

2 Nanobiophysics, MIRA Institute for Biomedical Technology and Technical Medicine & MESA+ Institute for Nanotechnology, University of Twente, Zuidhorst 164, Dienstweg 1, Enschede 7522ND, The Netherlands

* Author to whom correspondence should be addressed; E-Mail: a.cambi@ncmls.ru.nl; Tel.: +31-243-617-600; Fax: +31-243-540-339.

Received: 15 February 2013; in revised form: 2 March 2013 / Accepted: 11 March 2013 / Published: 25 March 2013

Abstract: Many processes regulating immune responses are initiated by G-protein coupled receptors (GPCRs) and report biochemical changes in the microenvironment. Dendritic cells (DCs) are the most potent antigen-presenting cells and crucial for the regulation of innate and adaptive immune responses. The lipid mediator Prostaglandin E2 (PGE2) via four GPCR subtypes (EP1-4) critically regulates DC generation, maturation and migration. The role of PGE2 signaling in DC biology was unraveled by the characterization of EP receptor subtype expression in DC progenitor cells and DCs, the identification of the signaling pathways initiated by these GPCR subtypes and the classification of DC responses to PGE2 at different stages of differentiation. Here, we review the advances in PGE2 signaling in DCs and describe the efforts still to be made to understand the spatio-temporal fine-tuning of PGE2 responses by DCs.

Keywords: PGE2; G-protein coupled receptors; EP2; EP4; dendritic cell
Abbreviations: Gβ, Gγ, heterotrimeric guanine nucleotide-binding proteins; Gαs, stimulatory guanine nucleotide binding protein; Gαi, inhibitory guanine nucleotide binding protein; AC, adenylate cyclase; AMP, adenosine monophosphate; cAMP, cyclic 3,5-adenosine monophosphate; PKA, protein kinase A; GSK-3α, glycogen synthase kinase-3; PI3K, phosphatidyl-inositol 3 kinase; Akt, also known as Protein Kinase B; CREB, cAMP response element–binding protein; Tcf, T-cell factor; Lef, lymphoid enhance factor; ERK, extracellular signal-regulated kinase; EGR-1, early growth response protein 1; GRK, G-protein coupled receptor kinase.

1. G-Protein-Coupled Receptor Signaling

The ability of cells to communicate with and respond to their external environment is critical for their survival and function. G-protein-coupled receptors (GPCRs) constitute a large and diverse family of proteins, which are crucial intermediates in the transmission and translation of extracellular information into intracellular responses [1]. The GPCR signaling cascade starts by binding a ligand to its receptor, thereby activating downstream signaling pathways, which finally result in complex cellular responses. The signaling and trafficking properties of GPCRs are often highly malleable depending on the cellular context. Receptor-interacting proteins that are differentially expressed in distinct cell types can attribute such plasticity of GPCR function. In addition, the spatiotemporal fine-tuning of a cell’s response to extracellular signals also depends on the probability of interaction between the receptor and its interaction partners, and this is controlled by the organization and lateral mobility of the signaling components within the plasma membrane [2–7]. Mechanisms exist that can control receptor localization and mobility, such as compartmentalization caused by cytoskeletal contacts, lipid environment or protein-protein interactions. Unraveling the mechanisms controlling GPCR signaling may lead to novel therapeutic approaches for treating diseases since GPCRs are amenable drug targets.

1.1. Immune Regulation by Dendritic Cells

Immune diseases and cancer are caused by a derailed or ineffective immune system. Understanding the molecular mechanisms that shape an effective immune response is a fundamental question in biology and essential towards the development of novel therapeutics.

Immune responses are orchestrated by a diverse group of functionally specialized, highly differentiated hematopoietic cell lineages. Dendritic cells (DCs) are the most effective antigen (Ag) presenting cells that play a central role in the induction of T-cell-mediated immunity [8]. In addition to activating the immune response, DCs are also decisive in creating tolerance. The pathway that is activated depends on the final balance between incoming signals [9]. In response to antigen uptake and exposure to inflammatory stimuli, DCs undergo a dramatic phenotypic conversion from a tissue resident, Ag-capturing cell to a highly migratory Ag-presenting cell, a process known as DC maturation. Activated DCs run an intricate migration track throughout the body involving the migration from peripheral tissues towards and their entry into the lymphatic vessels, as well as their final positioning in T-cell areas within the lymph nodes where they stimulate naïve T cells and initiate immune responses [8]. DCs are being exploited in the clinic for boosting immunological responses against various cancers by vaccination of cancer patients with ex vivo-generated autologous DC loaded
with tumor antigens. However, although immunological responses are observed in most studies, clinical responses are limited to a minority of patients. The success of DC-based immunotherapy in inducing cellular immunity against tumors is highly dependent on accurate delivery and trafficking of the Ag-loaded DC to T-cell-rich areas of secondary lymphoid tissues [10,11]. Therefore, in order to improve the clinical outcome, it is of the utmost importance to understand the molecular mechanisms that regulate the differentiation, maturation and migration of DC in order to optimize and steer the immune-regulatory capacities of \textit{ex vivo}-generated DCs.

While extensive research addresses the role of chemokines and cytokines in DC function [12], only recently the role of lipid mediators in DC differentiation and function has been highlighted, when their indispensable role in the DC lifecycle became clear [13–16]. DC differentiation from hematopoietic stem cells (HSCs) and DC function are sensitive to sources of lipid mediators, such as prostaglandins, and DCs express several receptors involved in prostaglandin signaling pathways [17]. Prostaglandin E2 (PGE$_2$) is a key modulator of DC differentiation from their specific progenitor cells [18], DC maturation, migration and production of cytokines to influence T cell differentiation [19–22]. Depending on the site of encounter and the maturation stage, PGE$_2$ acts both as an immunomediator and as an immunosuppress in DCs, exerting a stimulatory function for immature DCs in peripheral tissues [19], and an inhibitory function for mature DCs in the lymph nodes [23]. Finally, PGE$_2$ differentially regulates cytokine production by DCs as a response to the context and changes in the microenvironment [22,24,25].

1.2. PGE$_2$ Signaling

The lipid mediator PGE$_2$ is a cyclooxygenase (COX) metabolite of arachidonic acid and exhibits the most versatile actions in a wide variety of tissues, modulating various pathological and physiological activities, such as cancer, fever, inflammation, atherosclerosis, blood pressure, stroke, and reproduction [26,27]. Arachidonic acid is modified by the constitutively active COX-1 and the inducible COX-2 producing prostaglandin H, which is further converted by three different PGE synthases, a cytosolic PGE synthases (cPGES) and two membrane bound PGE synthases (mPGES1 and mPGES2). cPGES and mPGES2 are constitutive active, whereas mPGES1 is inducible [28]. Finally, PGE$_2$ is degraded by 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the hydroxyl group is oxidized into 15-keto metabolites which exhibit greatly reduced biological activities [29,30].

PGE$_2$ biological actions have been attributed to its interactions with specific GPCRs localized at the plasma membrane [17]. PGE$_2$ is believed to act in an autocrine and a paracrine manner via a family of four cell surface or nuclear membrane GPCRs termed EP1-EP4, with distinctive signaling pathways [31]. EP1 is coupled to Ga$q/p$ and activates phosphoinositide-phospholipase C (PLC), which ultimately leads to an increase in intracellular Ca$^{2+}$ [32]. EP2 and EP4 are coupled to the stimulatory G$\alpha_s$, which leads to an increase in intracellular adenosine-3',5'-cyclic monophosphate (cyclic adenosine monophosphate or cAMP) upon activation. Additionally EP4 has been described to be coupled to a Pertussis toxin-sensitive inhibitory G-protein, G$\alpha_i$ [33]. This will be discussed in more detail in the next paragraph. EP3 exists in three isoforms, all activating G$\alpha_i$, which decrease cAMP production. Mouse studies suggest that the activation of these receptors induce multiple physiological functions: for example it mediates stress responses [34,35], it facilitates ovulation and fertilization [36], it
regulates duodenal secretion [37] and it induces bone formation [38]. The specificity and diversity of PGE2 effects can be explained by the local PGE2 concentration due to the balance between its COX2-regulated synthesis and 15-PGDH-driven degradation, along with the characteristic expression pattern of different EP receptors with distinctive signaling mechanisms.

PGE2 stimulates a broad spectrum of responses throughout most immune cells as reviewed in [39]. For example, PGE2 selectively suppresses effector functions of macrophages and neutrophils and the Th1-, CTL-, and NK cell-mediated type 1 immunity at micromolar concentrations and stimulates Th1 and Th17 at nanomolar concentrations [40]. In addition, PGE2 supports differentiation, maturation and migration of DCs but suppresses their ability to attract naive, memory, and effector T cells. PGE2 regulates the immune response towards Th2 and Th17 immunity and enhances the local accumulation of regulatory T cells and myeloid-derived suppressor cells [41,42].

Dependent on DC subtype and species (human or mouse), DCs were shown to express either EP2 and EP4 or all four EP receptors, however PGE2 exerts its effects only via EP2 and EP4 (Figure 1) [19,21,26,43,44]. The distinguishing feature of the EP2 and EP4 receptors is that their signaling is predominantly transduced by Gαs, through which receptor activation is associated with an increase in adenylate cyclase activity and subsequently elevated intracellular cAMP levels [45,46]. However, EP4 ligation induces a weaker stimulation of intracellular cAMP when compared to the ligation of EP2 expressed at similar levels, although EP4 is known to have a higher affinity for PGE2 [47]. The production of cAMP and subsequently protein kinase A (PKA) leads to the phosphorylation of glycogen synthase kinase-3 (GSK-3) stimulating Tcf/Lef transcriptional activity. However, although EP4 is able to activate this signaling pathway, EP4 primarily induces Tcf/Lef transcriptional activity via a phosphatidylinositol 3 kinase (PI3K)-dependent pathway [48] through activation of Gαi [33,49]. In addition, EP2 and EP4 differentially regulate the PGE2-mediated phosphorylation of the cAMP response element–binding protein (CREB), central to the regulation of cAMP responsive gene expression: EP2 stimulates the PKA- and EP4 mainly the PI3K-dependent pathway [50]. In contrast to EP2, EP4 induces the functional expression of early growth response factor-1 (EGR-1) via the PI3K/MAPK signaling pathway [47], which can result in the expression of PGE2 synthase [51]. This can act as a positive feedback loop in which ligation of EP4 by PGE2 leads to an increase in PGE2 production via PGE2 synthase. Another distinguishing feature of EP4 is its ligand-induced desensitization and internalization [48,52], depending on elements present in the carboxyl terminus of EP4. The carboxyl terminus of EP4 also contains sites for potential phosphorylation by G-protein coupled receptor kinases (GRK) [53], and arrestin-2 binding promotes EP4 internalization [54]. However, so far mutation of multiple potential GRK phosphorylation sites did not alter agonist-induced internalization [55], suggesting a different or more complex arrestin-EP4 binding mechanism [54]. EP2 has a much shorter C-tail than EP4, which could be a possible explanation for its desensitization- and internalization resistance and lack of arrestin-2 binding. Indeed, an arrestin mutant that binds and desensitizes regardless of phosphorylation status of the receptor did promote EP2 internalization and attenuate EP2 receptor signaling [54].
**Figure 1.** Signaling pathways activated by PGE2 stimulation of the human EP2 and EP4 prostanoid receptors. Phosphorylation of GSK-3α via either PKA or PI3K signaling pathway inhibits the kinase activity of GSK-3α. Inhibition of GSK-3α stabilizes β-catenin that results in a decrease in its degradation and promotes β-catenin nuclear translocation and transcriptional activity of Tcf/Lef-regulated genes. Activation of either PKA or PI3K signaling pathway leads to phosphorylation of the transcription factor CREB regulating cAMP responsive gene expression. Activation of the PI3K/ERK pathway induces functional expression of EGR-1, known to regulate PGE2 synthase. In addition, PI3K signaling pathway inhibits the activity of PKA.

**1.3. PGE2 and Hematopoiesis**

PGE2 has a prominent role in controlling the number of hematopoietic stem cells (HSCs) from the bone marrow [56,57], but also HSC present in cord blood [58]. Although all four PGE2 receptors were expressed in HSC at protein as well as at mRNA level [59], in the hematopoietic system only EP4 seems operative as recently shown [60]. In vitro exposure of HSCs to PGE2 leads to better homing, survival and proliferation. The exposure of HSCs has profound influences on the enhanced expression of the C-X-C chemokine receptor type 4 (CXCR4) and survivin while the activity of caspase-3 is down-regulated, both processes inhibit apoptosis [61]. The CXCR4 receptor enhances the migration to stromal cell-derived factor-1 (SDF-1) *in vitro* and homing to the bone marrow *in vivo* [59]. Treatment *in vitro* and *in vivo* of HSC with PGE2 results in an increase in stem cell numbers [57]. Dissecting the identity of the responding HSC showed that long term HSCs were unaffected by PGE2 and that the
increase in HSC number was due to an expansion of the short term HSCs [62]. The latter HSC has less renewal capacity. Presently it is unknown if the long term HSC lacks the receptors for PGE$_2$ or whether other downstream processes are modified. PGE$_2$ signaling raises the level of $\beta$-catenin that is part of the Wnt signaling pathway that drives hematopoiesis [63]. The link between PGE$_2$ and Wnt was pinpointed at LGR5, a molecule expressed by (cancer) stem cells and a Wnt target. The level of expression of LGR5 was upregulated by PGE$_2$ [64]. Recently, it was shown that the upregulation of $\beta$-catenin is modulated via EP4 only [60]. Furthermore, PGE$_2$ appears to have a dual effect by stimulating the HSC but also the HSC supporting niche, again via the EP4 receptor [60].

After a massive expansion step, HSC differentiate into the eight different blood cell types. Most of these blood cells are insensitive to PGE$_2$ since blocking of PGE$_2$ production does not influence the differentiation of T cells, B cells and NK cells. In contrast, the number of monocytes increases and the number of DCs decreases after blocking PGE$_2$ synthesis with indomethacin [18]. Optimal development of DCs is regulated by PGE$_2$ via the EP1 and EP3 receptor. Triggering increases the receptor for Flt3, which is an important cytokine in DC development [60]. Thus, PGE$_2$ has regulatory properties on several stages of development of the hematopoietic system, these modulating effects being mediated by different receptor expression patterns.

1.4. PGE$_2$ Responses in Dendritic Cells

Various studies have demonstrated a multifaceted response of DCs to PGE$_2$. In particular, it recently became clear that the timing and extent of DC exposure to this lipid determine different cellular outcomes. *Ex vivo*, DCs can be generated through differentiation of peripheral blood monocytes in the presence of interleukin-4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF) [65,66]. These moDCs are a well-established system to study DCs and they are currently also exploited in several anti-tumor clinical trials [10,67]. Differentiation of inflammatory monocytes into DCs has been shown to also occur *in vivo* [68], thus making the moDCs a valid model cell system.

The generation of DCs from peripheral blood monocytes has been shown to be inhibited in the presence of PGE$_2$, either exogenously added or secreted by co-cultured mesenchymal stem cells [69]. More recently, Kalinski and colleagues demonstrated that a positive feedback loop between PGE$_2$ and its synthesizing enzyme COX2 is able to redirect the differentiation of monocyte cultures towards stable myeloid-derived suppressor cells, which have opposing role in the immune system as compared to DCs [70]. In contrast to its inhibitory effects on monocytes, PGE$_2$ exhibits an activating function on the immature moDCs. In fact, PGE$_2$ is a key regulator of DC maturation, in particular responsible for the acquisition of a migratory phenotype. As a first step towards the transition from an adhesive to a highly migratory state, DCs dissolve specific integrin- and actin-rich adhesive structures called podosomes within minutes after PGE$_2$ stimulation [20,71]. This fast response to PGE$_2$ is mediated by elevation of cAMP intracellular levels, activation of the small GTPase RhoA and subsequent induction of actomyosin contraction ultimately leading to fast podosome dissolution [21]. Combined with proinflammatory cytokines, PGE$_2$ specifically upregulates the surface expression levels of the chemokine receptor CCR7, which is responsible for the chemotactic responsiveness of DCs to lymph node-derived chemokines such as CCL19 and CCL21 [72]. Furthermore, prolonged incubation of DCs
with PGE2 induces expression of matrix metalloproteinase 9 (MMP-9), which together with CCR7 is responsible for the directional migration of DCs to draining lymph nodes [73,74]. It should be noted that to enable DC chemotaxis, PGE2 addition is absolutely required at early time points of maturation, as addition of PGE2 during terminal maturation stages is no longer effective [19].

Besides stimulating DC migration, PGE2 plays also a role in enhancing the T cell stimulatory capacity of DCs by inducing the upregulation of costimulatory receptors such as OX40L, CD70 and 4-1BBL early during DC maturation that results in an increased capacity to induce proliferation of CD4+ and CD8+ T cells [75], despite the concomitant induction of several suppressive factors like thrombospondin-1 [76] and IDO [77], known to suppress T cell proliferation and survival promoting tolerance. In addition, DC function is influenced by the production of specific cytokines. PGE2 induces IL-10 production, a known inhibitor of DC maturation [78] and suppresses the production of IL-12, shifting the balance from a Th1 to a Th2 response [79,80]. A very recent study by Woodward and colleagues demonstrated that PGE2 can differentially regulate DC production of cytokines depending on the EP receptor that is stimulated [81]. For example, low concentrations (up to 10 nM) of PGE2 appear to stimulate the Th17 response supporting IL-23 release via EP4 [82], whereas at concentrations higher than 50 nM PGE2 inhibits IL-23 production in an EP2 dependent manner [81]. These novel findings indicate that subtle changes in PGE2 concentration in the extracellular microenvironment can specifically activate one particular receptor thus differentially modulating cellular responses.

Interestingly, the effects of PGE2 on naturally occurring DC subsets seem to be quite diverse. For example, signaling of PGE2 through EP4 was found to facilitate the initiation of skin immune responses by enhancing maturation and migration of Langerhans cells [43]. In contrast, on human plasmacytoid DCs (pDCs) PGE2 has been shown to potently inhibit secretion of IFN-alpha by pDCs upon stimulation with Toll-like receptor ligands, with subsequent decreased secretion of Th1 cytokines by co-cultured T cells [83]. PGE2 inhibits IFN-alpha secretion and Th1 costimulation by human pDCs via EP2 and EP4 engagement [84]. PGE2 can therefore be considered as a negative regulator on human pDCs [85]. Considering the large variety of properties and functions of the various DC subsets, might lead to multiple cellular responses. This once again highlights the complexity and multifaceted action of PGE2 signaling in DCs.

2. Outlook

PGE2 acts both as an immunosuppressor and an immunoactivator throughout the lifecycle of DCs (Figure 2). Therefore, knowledge on the complexity of PGE2 signaling is necessary in order to predict, control and intervene in the PGE2 response in experimental and possibly clinical settings. The different cellular effects mediated by PGE2 in DCs marginally depend on the expression pattern of the EP receptors. Although differentiation of DCs seems regulated via EP1 and EP3, the function of DCs during their lifecycle is always regulated via EP2 and EP4. Therefore, the expression levels of EP2 and EP4, their different affinity for PGE2 and the extent of activation of the different signaling pathways downstream of EP2 and EP4 will enable a DC to tune cellular outputs in response to PGE2. The extent of EP2 and EP4 activity is critically dependent on the probability of interaction between the receptor and receptor-interacting proteins, like Gαs, Gαi and arrestin, and subjected to precise regulation of
localization in time and space. Furthermore, cross talk of the EP2 and EP4 signaling pathways might occur as well as cross talk by different receptors, influencing the availability of receptor interacting partners or downstream signaling proteins. To fully understand PGE\(_2\) regulated processes in DCs, all individual molecular interactions should be followed in space and time, which would allow us to build a dynamic and quantitative signaling network connectivity-map for prediction of the DC response to PGE\(_2\) based on parameters like for example, receptor numbers, affinities etc. With the rapid development and improvement of high-resolution bioimaging techniques suited for the investigation of fast signal transduction processes at the molecular level [86], we expect to be able to simultaneously investigate multiple molecular interactions involved in the PGE\(_2\) receptor signal cascade, which might represent a paradigm for other GPCR signaling pathways.

**Figure 2.** The multifaceted roles of PGE2 during the lifecycle of dendritic cells.

**Acknowledgments**

Work in the author’s laboratory is supported by a HFSP young investigator grant awarded to AC and by a grant from the Dutch government to the Netherlands Institute for Regenerative Medicine (NIRM, grant No. FES0908). AC is the recipient of a Meervoud grant (836.09.002) from the Netherlands Organisation for Scientific Research (NWO). The authors would like to thank Stefan Janssen for assisting in the preparation of this review.

**Conflict of Interest**

The authors declare no conflict of interest.

**References**


64. Al-Kharusi, M.R.; Smartt, H.J.; Greenhough, A.; Collard, T.J.; Emery, E.D.; Williams, A.C.; Paraskeva, C. LGR5 promotes survival in human colorectal adenoma cells and is upregulated by PGE2: Implications for targeting adenoma stem cells with NSAIDs. Carcinogenesis 2013, [Epub ahead of print].


© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).